Fluzoparib Combined With Dalpiciclib for Platinum Resistant Recurrent Ovarian Cancer
Interventionnel
Phase 2
Fudan university shanghai cancer center, Deparment of gynecologic oncology
Sponsor: Fudan University
Dernière synchronisation : 14 août 2024 Avis - Les informations proviennent de registres publics et peuvent ne pas refléter les changements en temps réel sur le site local.
This study aims to investigate the safety and efficacy of combination therapy of Fluzoparib combined With Dalpiciclib for platinum-resistant recurrent ovarian cancer through a single-center, prospective, single-arm, phase II clinical trial, to improve the overall treatment level and prognosis of platinum-resistant ovarian cancer.